Product Overview
Dragon Pharma BPC 157 ships as one lyophilised vial holding 5 mg of the pentadecapeptide. The molecule is fifteen amino acids long and comes from a fragment of a protein found in gastric juice, which is why the older name for it is body protection compound. Production follows GMP practice and the peptide mass is printed on the label, so concentration is calculated from the volume of solvent added rather than estimated from a fill line. It is a laboratory reference material and not an approved medicine, and that status does not change with dose or route.
The research interest behind the vial is animal work. Rodent models have used this peptide in tissue repair and gut protection protocols, and the elimination half-life measured in those studies runs between 7.9 and 30 minutes after intravenous or intramuscular administration. No human half-life has been established, which is why a 2025 review of the clinical literature describes the human evidence base as limited. Researchers who want a second repair peptide on the bench usually order TB 500, and a pre-combined format exists as BPC-157 and TB-500 blend.
The vial fits laboratory and reference work where the readouts are tissue-level and the timelines are measured in weeks. Community descriptions concentrate on local application near tendons and joints, and short courses are usual simply because no validated duration exists in the literature. Every vial needs a solvent, so Bacteriostatic water is the natural companion purchase. Anyone subject to testing should note that the peptide is named in WADA class S0 and is prohibited at all times.
Dosage Protocol
There is no approved human dose for this peptide, so the figures below are the research and vendor reference values that are published for the material rather than clinical instructions. The arithmetic that follows is taken from the vendor method and scaled to the 5 mg fill of this vial.
| Research amount | 250-500 mcg per day is the amount quoted in vendor descriptions; no confirmed human dose exists |
| Course length | Short courses are the community norm; no validated duration is published |
| Route | Subcutaneous or intramuscular; community write-ups describe local application near the tissue of interest |
| Reconstitution | Bacteriostatic water; the vendor reference uses 5 mg with 2 ml of solvent, where 250 mcg equals 10 units on a U-100 scale |
| Female | No separate protocol was found; there is no established human dose for either sex |
| Administration | Rotate the injection site and keep the injected volume small; the active life of the peptide is measured in minutes rather than days |
Stacking and Combinations
Sources describe no fixed combination protocol for this peptide, so the cards below show the reference groupings that appear in practice rather than a validated plan. Each pill links to the product page and every item lives inside the Dragon Pharma section.
What to Expect
- Timelines. Human timelines are not established; the published effect data come from animal models, so expectations are built on vendor descriptions instead.
- Reported comfort change. Users often describe less discomfort around tendons and joints within the first week or two of a short block.
- Safety reading. The literature notes few serious events, but systematic human safety data are missing, so absence of reports is not evidence of a clean profile.
- Half-life limit. The 7.9-30 minute figure was measured in rats; the short window is the main argument for repeated or local administration.
- Handling burden. This is a research product, so sterility and dosing accuracy rest entirely with the user and the solvent used.
- Testing status. The peptide appears in the 2026 WADA list in class S0, which matters to any athlete under a testing programme.
- Cold chain. A reconstituted solution needs refrigeration, and the exact shelf life for this 5 mg vial is not confirmed in the sources used here.
Side Effects and Management
Reported events are mostly local and mild. The larger issue is that controlled human data are thin, so management decisions are based on technique and observation rather than on a documented risk profile.
Reconstitution and Storage
Handling is the part of this vial that is fully documented, so these rows collect the practical reference values. Related research materials from the same section include MOTS-c, GHK-CU and Tesamorelin.
